AbbVie launches multi-tranche debt offering to fund $10.9B Apogee acquisition
ABBV sits 30% above its 52-week low of $189.785.
Summary
AbbVie is issuing senior notes across nine tranches to fund its pending $10.9 billion acquisition of Apogee Therapeutics. The offering includes a special mandatory redemption feature that protects bondholders if the acquisition is terminated.
Key Events · Financing and Capital Events · ABBV
-
Debt Offering to Fund Apogee Acquisition
To fund a portion of its $10.9 billion acquisition of Apogee Therapeutics, AbbVie is offering nine tranches of senior notes, including floating rate and fixed rate notes. The net proceeds are expected to be approximately $[amount] billion.
-
Special Mandatory Redemption Feature
Seven of the nine tranches are subject to a special mandatory redemption at 101% of principal plus accrued interest if the Apogee acquisition agreement is terminated. The two long-term notes are not subject to this redemption.
-
Bridge Loan Reduction
The net proceeds from this offering will reduce commitments under AbbVie's $10.0 billion 364-Day Delayed Draw Term Loan Facility, which was established in July 2026 as bridge financing for the acquisition.
-
Use of Proceeds
Proceeds will be used to fund the Apogee acquisition and for general corporate purposes, which may include repaying or repurchasing outstanding debt.
Analysis · ABBV · Life Sciences
To finance its $10.9 billion acquisition of Apogee Therapeutics, AbbVie is tapping the bond market with a multi-tranche senior notes offering. A special mandatory redemption feature on seven of the nine tranches protects investors—if the Apogee deal falls through, those notes must be redeemed at 101% of principal. This structure signals AbbVie's commitment to closing the acquisition. The offering will reduce commitments under a $10 billion bridge loan, replacing short-term bank debt with longer-term bond financing. For a company of AbbVie's size, this is a routine capital markets execution, but the size and the acquisition context make it a notable event.
At the time of this filing, ABBV was trading at $247.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $433B. The 52-week trading range was $189.79 to $267.47. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.